Description

Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist developed for metabolic and hepatic research applications. Unlike pure GLP-1 receptor agonists, Survodutide engages both glucagon and GLP-1 receptors, combining the appetite-suppressing and insulin-sensitizing effects of GLP-1 agonism with the thermogenic and hepatic lipid-reducing effects of glucagon receptor activation. This dual mechanism has been investigated in clinical research for its effects on metabolic endpoints including body composition, liver fat content, and markers of metabolic-associated steatotic liver disease (MASLD). The glucagon receptor component promotes hepatic fat oxidation, energy expenditure, and amino acid catabolism, providing distinct metabolic benefits. Supplied as a lyophilized powder. For research use only.